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ORIGINAL ARTICLE
Neonatal outcomes and congenital anomalies in pregnancies affected by
hypothyroidism
Zareen Kirana , Aisha Sheikha , Khadija Nuzhat Humayunb and Najmul Islama
aSection of Endocrinology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan; bClinical Fellowship in Paediatric
Endocrinology, Paediatrics & Child Health, Aga Khan University Hospital, Karachi, Pakistan
ABSTRACT
Background: Maternal hypothyroidism has been reported to have concerns over neonatal out-
comes, not only in the context of neurocognitive development but also in the short term as
birth weight and neonatal jaundice.
Patients and methods: We conducted a cross-sectional retrospective study on 638 cases who
delivered live births in the Aga Khan University Hospital after ethical approval. Data were col-
lected on hypothyroid pregnant females who were diagnosed before conception or during their
antenatal visits during the year 2008–2016. Neonatal outcomes were noted for birth weight,
maturity, and neonatal jaundice, neonatal hypothyroidism, neonatal respiratory distress syn-
drome, sepsis, hypocalcaemia, congenital anomalies, need for intensive care admission, and neo-
natal death. Subgroup analysis was performed on the timing of diagnosis of maternal
hypothyroidism. Data analysis was performed on Statistical Package for the Social Sciences ver-
sion 20.0.
Results: Neonatal jaundice was the most common neonatal outcome (37.6%) in our cohort of
662 live births. Nearly 15% required intensive care unit admission, however, neonatal death was
very rare. The most common clinically significant congenital anomalies were cardiovascular
defects, whereas Mongolian spots were the commonest congenital condition to report. There is
a statistically significant association between low birth weight (OR 1.86, 95% CI 1.0–3.2, p 
0.05) and congenital anomalies (OR 2.39, 95% CI 1.4–4.0, p  0.05) with women diagnosed with
hypothyroidism before pregnancy.
Conclusion: We report the neonatal outcomes and spectrum of congenital anomalies of hypo-
thyroid pregnancies diagnosed before and during conception for the first time from the region
of Pakistan.
KEY MESSAGE
 Overall, none of the neonates of hypothyroid pregnancies developed congenital
hypothyroidism.
 Cardiovascular defects in these neonates imply extensive screening and monitoring dur-
ing pregnancy.
 Low birth weight and congenital anomalies are associated with the timings of diagnosis of
hypothyroidism in pregnancy.
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Overt hypothyroidism occurs in 2–3% of pregnancies
[1] and is well reported to be associated with compli-
cations including gestational hypertension (GH) and
pre-eclampsia [2–4]. Maternal hypothyroidism also has
a number of adverse neonatal outcomes such as low
birth weight and preterm birth [5,6] and impaired neu-
rocognitive development in early life of the child [7].
Thyroid hormones appear to have their most profound
effect on the terminal stages of brain differentiation,
including synaptogenesis, growth of dendrites and
axons, myelination and neuronal migration [8]. The
timing of vulnerability of brain to iodine as well as
thyroid hormone deficiency is within the first 12weeks
of pregnancy until the baby’s thyroid begins to pro-
duce its own thyroid hormone. Therefore, iodine and
thyroid supplementation in the third trimester or dur-
ing neonatal life doesn’t improve neurological
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outcome [4]. In a case–control study published in
1999, researchers found larger deficit in tests related
to intelligence, attention and school performance
among children of untreated hypothyroid mothers
when compared to children belonging to mothers of
the controlled group [9]. Hence if left untreated, hypo-
thyroid pregnancies results in birth of neurological
cretin (characterized by neurological, cognitive impair-
ment etc.) [10,11]. Subclinical hypothyroidism has an
estimated prevalence rate of 2–5% of all cases [12,13]
and is associated with preterm birth [14]. Early placen-
tal development by trophoblastic proliferation and
invasion requires critical role of thyroid hormones
[7,13]. An important risk factor for preterm delivery
would be failure of adequate placentation which may
result from maternal thyroid deficiency [6,15,16].
Similar mechanism is contributing towards low APGAR
(Appearance, Pulse, Grimace, Activity, and Respiration)
score and placental abruption leading to stillbirth [3].
Maternal hypothyroidism has also been associated
with several congenital anomalies [17,18]. Studies are
still difficult to validate strong association of either
uncontrolled maternal hypothyroidism or use of levo-
thyroxine drug during pregnancy as a significant risk
factor behind these congenital defects or adverse neo-
natal outcomes [19–21].
We therefore aim to report the neonatal outcomes
and congenital anomalies of pregnancies affected by
hypothyroidism from a tertiary care centre for the first
time from the region of Pakistan.
Materials and methods
Ethics approval and consent to participate
The study was approved by The Aga Khan University’s
ethical review committee (ERC number: 3977-Med-
ERC-15). The study was performed under Helsinki’s
ethical principle. To preserve confidentiality, we coded
each patient and removed their original identifications.
Informed consent was based on hospital consent pol-
icy at the time of admission or clinic visit. Moreover,
the principle of Justice, Beneficence and Non-
Maleficence was maintained and followed throughout
the conduct of this study.
Patient selection
We conducted a cross-sectional retrospective chart
review of neonates of hypothyroid pregnant patients
delivered at the Aga Khan University Hospital. Data
was collected by trained medical students. It was ran-
domly double-checked and corroborated by the
principal investigator. We reviewed the medical record
files of neonates of the mothers who were either a
known case of hypothyroidism (overt as well as sub-
clinical) or were diagnosed during their antenatal vis-
its, during the year 2008–2016. We determined the
timing of diagnosis of hypothyroidism (newly diag-
nosed as well as previously diagnosed) through data
recorded by their primary physicians (endocrinologist
or obstetricians) in relation to the gestation during the
study period. We started the file review of the most
recent case. We noted the data from neonatal files
including neonatal TSH level of 2nd or 3rd day of life
(whichever available).
We selected neonates born to mothers who were
diagnosed hypothyroid according to the following
inclusion criteria: All pregnant women attending endo-
crine and obstetric clinic who had been diagnosed
overt [thyrotropin (TSH) > 2.5 mIU/l and low free
tetra-iodothyronine (FT4) OR TSH > 10 mIU/l only] or
subclinical (TSH 2.5 10 mIU/l and normal FT4) hypo-
thyroidism either before or during pregnancy. Patients
were either on levothyroxine replacement or newly
started according to their presentation. Maternal char-
acteristics and maternal outcomes of these neonates
have already been published in a separate article
(MHPO-1) [22]. Pregnancies with any abnormal thyroid
function tests that did not fit into the overt or subclin-
ical hypothyroidism criteria by American Thyroid
Association were excluded from the study [23].
Definitions of outcomes and congenital anomalies
Gestational age at birth (weeks):
We divided the gestational age at birth into
“extremely preterm (<28)”, “very preterm (28–31)”,
“late preterm (32–36)”, “term (37–42)” and “post-term
(>42)”. Birth Weight: Defined as “Low (<2500 g)”,
“Appropriate (2500–4000 g)” and “Large (>4000 g)”.
Low APGAR score at 5min: Assessment of physical
health is noted in the one-minute APGAR score
(scored from 0 to 10) and then again at five minutes
to assess how the baby has responded to any resusci-
tation attempts. A score below 7 is considered low at
5min. Respiratory complications (including respira-
tory distress syndrome, neonatal sepsis, and need for
phototherapy): As indicated by the physician’s notes.
Neonatal jaundice: Total bilirubin levels above
17 mmol/L checked within 48–72 h of birth.
Hypocalcaemia: Serum calcium levels below the refer-
ence range defined for neonates in our hospital, that
is, 146.2–173.4 mmol/L checked at any time after birth
till hospital discharge. NICU (neonatal intensive care
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unit) admission: Neonates requiring ICU admission for
24 h or more. Neonatal death: Classified further as
early; if occurs in less than 7 days or late; if occurs
between 7 and 28 days of life. Congenital anomalies
are defined using International Classification of
Diseases (ICD-10) codes Q00-Q99 but excludes “inborn
errors of metabolism” (codes E70-E90). Conditions of
clinical importance like cardiovascular defects, nervous
system defects and urogenital anomalies were
grouped separately. Rest of the conditions of less clin-
ical importance were also noted and detailed in
the results.
Statistical analysis
The results of demographic and clinical features are
presented as mean± standard deviation for quantita-
tive variables and number (percentage) for qualitative
variables. Proportional differences were assessed by
using the Chi-square test or Fisher exact test where
appropriate. For the purpose of subgroup analysis, var-
iables of birth weight and gestational age at delivery
were recoded dichotomously into low birth weight
and premature birth. Unadjusted Odds ratio were cal-
culated for the effect of timing of diagnosis of hypo-
thyroidism on various neonatal outcomes and
congenital anomalies. We sought ethical approval
from the university’s ethical review committee (ERC
number: 3977-Med-ERC-15).
Results
Among 708 hypothyroid women recruited, 638 had
live births (Figure 1). The mean age of the hypothyroid
pregnancies was 31 years (SD 4.73). In our hospital,
there was variation in the timing of presentation of
women with respect to their gestational ages; how-
ever, almost two-third had presented in the first tri-
mester, with most visits noted in the 8th week. Most
of the patients were already diagnosed before preg-
nancy and subclinical hypothyroid cases were domi-
nating in the overall population. The serum TSH levels
were recorded in 53.2% and 56.7% cases in the pre-
conception and 1st trimester, whereas 61.7% and
66.6% of cases had their TSH levels available in the
second and third trimester periods.
Neonatal outcomes
Table 1 describes the detailed characteristics of neo-
natal outcomes. The mean gestational age at delivery
was 37.5weeks (SD 2.1). Neonatal jaundice was the
most frequent medical condition (37.6%), measured
on day 1–3 of life, with nearly half of the neonates
having total bilirubin levels between 85.0 and
170.0 mmol/L. Single session phototherapy was
required in almost 15% of neonates (Supplementary
File, Table 1). Neonates with total bilirubin <255 mmol/
L, requiring phototherapy were total 82 out of overall
98. Out of these, 25 had appropriate birth weight and
born at term and 7 had low birth weight at term.
Only one neonate had large birth weight at term
whose mother had diabetes as well as gestational
hypertension. Now out of those with appropriate birth
weight at term, 1 had Glucose-6-Phosphate dehydro-
genase (G6PD) deficiency, 1 had Down’s syndrome
and high TSH of 34.3 mIU/l. Eight mothers of these
neonates had gestational diabetes (GDM), 3 had dia-
betes mellitus (DM), 3 had GH/preeclampsia and 2 had
chronic hypertension. One mother also had past
obstetric history of Trisomy 18. Since none of our neo-
nates were diagnosed with congenital hypothyroidism
in the short-term (within a month), we did not analyse
the association of this level of hyperbilirubinemia with
neonatal TSH levels. Although majority of the respira-
tory complications were not detailed in the charts,
transient tachypnoea of newborn accounted for the
most (0.9%) of them, and only three cases (0.5%)





N = 36 (18x2)
Triplet pregnancy
N = 9 (3x3)
Figure 1. Flow chart for live births. Number of singleton, twin and triplet pregnancies.
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required ventilatory support. Sepsis was found
amongst 6.5% of the neonates, out of which 1.2%
were presumed to have sepsis, with only one case
each for bacterial pneumonia, acute gastroenteritis,
urosepsis, and meningitis. Out of 662 cases, 12%
required NICU admission, but neonatal death was
1.6%. Amongst our cohort (Supplementary File, Table
2), 92% of the neonates had birth weight appropriate
for gestational age at term; however, 56% were small
for gestational age at even late preterm. There were
five cases of large for gestational age, with only one
of them being born to a diabetic mother who also
had gestational hypertension. The median TSH of the
neonates was 4.18 mIU/l at 48 h of birth and only nine
neonates had a TSH of more than 20 mIU/l. The high-
est TSH recorded was 57.6 mIU/l.
Congenital anomalies
Twenty-two percent (147/662) of the neonates had
some forms of congenital anomalies, defects and con-
ditions (Figure 2) (Supplementary File, Table 3). So,
major congenital anomalies were classified into cardio-
vascular defects, nervous system defects and urogeni-
tal anomalies and accounted for 10.3% only. Overall,
48 neonates had two congenital defects and nine of
662 had three defects. Mongolian spots were the com-
monest congenital condition, but cardiovascular
defects were the highest clinically significant congeni-
tal anomaly. Out of two cases of Down syndrome, one
had a TSH of 34.3 uIU/L and the other had 11.0 uIU/L.
One child was found to have learning difficulty at
6.5 years of age.
Subgroup analysis of neonatal outcomes based
on timing of diagnosis of hypothyroidism
Pregnant women in our cohort were mostly diagnosed
with hypothyroidism prior to pregnancy (N¼ 565,
85.3%) with only 29 (4.4%) cases having no record.









Cardiovascular anomalies Neurological anomalies Urogenital anomalies
Gastrointesnal anomalies Musculoskeletal anomalies Miscellaneous anomalies
Congenital condions No anomalies
Figure 2. Major groups of congenital anomalies and conditions of neonates of hypothyroid women.





Gestational age at delivery (weeks)
Extremely preterm (<28) 1 (0.2)
Very preterm (28–31) 14 (2.1)
Late preterm (32–36) 121 (18.3)
Term (37–42) 526 (79.5)
Birth weight (g)
Low (<2500) 142 (21.5)
Appropriate (2500–4000) 512 (77.3)
Large (>4000) 5 (0.8)
Not documented 3 (0.5)
Respiratory complications 53 (8.0)
Sepsis 43 (6.5)
Hypocalcaemia 34 (5.1)
Neonatal Jaundice 66 (10.0)
Total Bilirubin 1.0–5.0 (mg/dl) 303 (45.8)
Total Bilirubin 5.1–10.0 199 (30.1)
Total Bilirubin 10.1–15.0 33 (5.0)
Total Bilirubin 15.1–20.0 61 (9.2)
Total Bilirubin not available
Need for phototherapy 98 (14.8)
APGAR at 1min 7.9 (± 0.6)
APGAR at 5min 8.9 (± 0.4)
Low APGAR at 5min (Score< 7) 3 (0.5)
NICU admission
Less than 24 h 10 (1.5)
More than 24 h 70 (10.6)
Neonatal TSH (at 48 h) (mIU/L) 4.1 (2.4–6.8)
Neonatal death
Early (<7days) 5 (0.8)
Late (between 7-28) 5 (0.8)
Data are expressed as mean ± standard deviation, median (percentiles
25–75), or frequencies.
APGAR: Appearance, Pulse, Grimace, Activity, and Respiration; NICU: neo-
natal intensive care admission; TSH: thyroid-stimulating hormone.
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before conception had significant association with low
birth weight and congenital anomalies in the neo-
nates. However, there was only marginally significant
association of premature birth and sepsis in the neo-
nates, with respect to these two groups. Other neo-
natal outcomes had no clinically significant association
with respect to the timings of diagnosis of hypothy-
roidism in pregnant women.
Discussion
Maternal hypothyroidism has been associated with
adverse neonatal outcomes in various studies [14,24].
Neonatal hyperbilirubinemia is reported to be a com-
mon condition caused by variety of factors in Asians
[25]. Studies from our city Karachi have also reported
11–13% prevalence of neonatal jaundice in general
population [26,27]. Our babies had varying degrees of
jaundice in the first month after birth as reported by a
recent study conducted in India [24], but none of
them was labelled to have congenital hypothyroidism,
which is one of the rare but overlooked cause of
severe and prolonged jaundice as reported in the lit-
erature [28]. Out of three cases of G6PD deficiency
reported in our neonates, two had hyperbilirubinemia,
and their TSH levels were not above the normal
laboratory range (1.0–39.0 mIU/l). Besides, there was
no reported case of ABO or Rh (Rhesus) incompatibil-
ity case in our cohort. Overall, these neonates should
be followed, either for the resolution or worsening of
jaundice, through a well-defined protocol in hypothy-
roid pregnancies.
Neonates of hypothyroid mothers in our hospital
had similar rate (12%) of NICU admission, as described
in the international literature. A recent Finnish study
reported 14.4% NICU admissions in a large cohort of
Table 2. Subgroup analysis of neonatal outcomes and congenital anomalies based on timing of diagnosis of hypothyroidism.
Neonatal outcomes
Diagnosis of maternal hypothyroidism





Low APGAR at 5min
Yes 0 (0.0%) 3 (0.5%) 1.000 1.12 1.09–1.15
No 68 (100.0%) 560 (99.5%)
Premature birth
Yes 20 (29.4%) 108 (19.1%) .055 1.76 1.00–3.09
No 48 (70.6%) 457 (80.9%)
Low Birth Weight
Yes 21 (31.3%) 111 (19.6%) .028 1.86 1.07–3.25
No 46 (68.7%) 454 (80.4%)
Respiratory distress syndrome
Yes 7 (10.3%) 42 (7.4%) .468 1.43 0.61–3.32
No 61 (89.7%) 523 (92.6%)
Sepsis
Yes 8 (11.8%) 31 (5.5%) .057 2.29 1.01–5.22
No 60 (88.2%) 534 (94.5%)
Hyperbilirubinemia
Yes 22 (32.4%) 213 (37.7%) .427 0.79 0.46–1.35
No 46 (67.6%) 352 (62.3%)
Need for Phototherapy
Yes 7 (10.3%) 85 (15.0%) .364 0.65 0.28–1.46
No 61 (89.7%) 480 (85.0%)
Hypocalcaemia
Yes 5 (7.4%) 26 (4.6%) .365 1.64 0.61–4.43
No 63 (92.6%) 538 (95.4%)
NICU admission less than 24 h
Yes 0 (0.0%) 10 (1.8%) .611 1.12 1.09–1.15
No 68 (100.0%) 555 (98.2%)
NICU admission more than 24 h
Yes 11 (16.2%) 55 (9.7%) .137 1.78 0.88–3.61
No 57 (83.8%) 510 (90.3%)
Neonatal death
Yes 1 (1.5%) 8 (1.4%) .643 1.03 0.13–8.43
No 67 (98.5%) 557 (98.6%)
Neonatal TSH groups (N¼ 588)#
<20 mIU/l 59 (96.7%) 522 (98.8%) .158 0.28 0.05–1.48
20 mIU/l 2 (3.3%) 5 (1.2%)
Congenital anomalies and conditions
Yes 26 (38.2%) 116 (20.5%) .001 2.39 1.41–4.07
No 42 (61.8%) 449 (79.5%)
p-value determined by chi square. p value 0.05 taken as significant. Fischer test applied. #Neonatal TSH were missing in 74 cases. $Unadjusted odds
ration was calculated.
APGAR: Appearance, Pulse, Grimace, Activity, and Respiration; NICU: neonatal intensive care admission; TSH: thyroid-stimulating hormone.
1564 Z. KIRAN ET AL.
16,364 hypothyroid mothers which was only slightly
higher (13%) than those mothers who were consist-
ently using levothyroxine replacement amongst them
(OR 1.09, CI 1.01–1.18) [18]. Similarly, a Nigerian study
also reported 16% NICU admission in babies of hypo-
thyroid mothers which was significantly higher than
babies of normal mothers (6.3%, p 0.05), although
the sample size was relatively small [29]. We had pro-
longed NICU stay (>24 h) in 10.6% of our neonates
and only 1.5% required <24 h NICU care. Although,
prospective case–control studies are required to fur-
ther elaborate on factors responsible for this preva-
lence of NICU admissions in our setup, neonates of
hypothyroid mothers are generally reported to require
increased NICU care than euthyroid mothers [30].
Overall, only 1.6% neonatal deaths occurred in our
cohort, which is considerably lower as compared to
4.2–13% as reported in local studies [31,32].
A recent cross-sectional study from Bangladesh has
reported maternal hypothyroidism to be present in
5.12% of babies born with congenital anomalies [17].
Studies from Pakistan have reported 5–7% prevalence
of congenital anomalies overall [33,34]. Several studies
are reported about the association of congenital
maternal hypothyroidism and the risk of neurodevel-
opment impairment of their children [35,36]. However,
data are still conflicting about this strong association
in mothers without congenital hypothyroidism; hence,
it is difficult to report this from the literature [19–21].
Majority of the mothers in our cohort had Hashimoto’s
disease as the aetiology of hypothyroidism, however,
only one patient had congenital hypothyroidism with
no congenital anomaly in her neonate. Our mothers
had their TSH levels aimed to be controlled below 2.5
mIU/l with varying requirement of levothyroxine dose
(results to be published in a separate paper, MHPO-5)
[22]. Besides congenital anomalies are more evidently
reported in co-existence with neonatal congenital
hypothyroidism [37,38]. Only nine neonates in our
study group had TSH raised more than 20 mIU/l and
none of them developed congenital hypothyroidism
on follow-up up to 1month. We therefore compared
our data with congenital hypothyroid neonates.
Neonates with Down syndrome are also found to have
congenital hypothyroidism along with other thyroid
disorders [39,40]. We had only two cases of Down syn-
drome and only one had TSH > 20 mIU/l, but there
was no hypothyroidism on follow-up up to 1month.
Another unique observation in our study is the higher
chance (OR 2.39, 95% CI 1.4–4.0, p 0.05) of congeni-
tal anomalies in the neonates of women diagnosed
hypothyroid prior to pregnancy as compared to those
diagnosed during pregnancy. A recent Spanish study
showed 53.7% women were diagnosed hypothyroid-
ism before pregnancy [41], and another large nation-
wide study from Finland reported perinatal and
pregnancy outcomes in hypothyroid women who had
pregestational (65.9%) as well as gestational (37.5%)
diagnosis based on levothyroxine purchases [18]. But
none of them compared the outcomes between these
two groups as reported in our study.
Most studies reported major congenital anomalies
as a perinatal outcome of hypothyroid mothers but
did not describe the details of the anomalies [18].
Among the significant congenital anomalies, our
cohort had more cardiovascular defects (CVD) with
highest prevalence of Patent Ductus Arteriosus (PDA)
(1.2%) followed by Ventricular Septal Defect (VSD)
(1.1%). Literature is limited regarding neonates of
hypothyroid mothers without congenital hypothyroid-
ism developing cardiovascular defects. A study from
India reported higher CVD than other anomalies
amongst congenital hypothyroid neonates [42], which
is similar to a Mexican study with a larger sample size
and with PDA as the second most common CVD [43].
Urogenital tract was the second clinically important
organ system involved in our neonates. A study from
Iran has reported significant association of presence of
urogenital anomalies with congenital hypothyroidism
(OR 2.04; 95%CI: 1.1–3.6; p 0.05) [38]. We also
observed that births to women diagnosed during
pregnancy are 2.3 times more likely to have a con-
genital anomaly or condition. We have no local data
to compare this effect, however, this subject is also
rarely explored in literature. One of our neonates also
had Zellweger syndrome and the other had Edward
syndrome, which have never been reported before.
Although there are number of miscellaneous cutane-
ous (most common Mongolian spots) and musculo-
skeletal conditions present in our cohort of neonates,
we need to identify their significance only after con-
ducting a case–control study.
Neonates in our cohort had significant association
with low birth weight (OR 1.86, 95% CI 1.0–3.2, p
0.05) in hypothyroid women diagnosed before preg-
nancy. This is in contrast to a large Danish registry,
which reported increased risk of high birth weight
associated with hypothyroidism in mothers (adjusted
difference 20 g, 95% CI 10–30 g) rather than low birth
weight which was actually associated with hyperthy-
roidism, even after adjusting for potential confounders
[44]. On the other hand, many studies have concluded
that maternal hypothyroidism had no significant asso-
ciation with low birth weight in early as well as late
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pregnancy [45,46]. However, other studies described
lower birth weight in the hypothyroid women as com-
pared to control groups (p 0.05) as reported in our
study [47]. However, no study has directly compared
this outcome with timing of maternal diagnosis of
hypothyroidism, which is the novelty described in
our study.
Our study also observed marginally significant asso-
ciation of premature birth (OR 1.76, CI 1.00–3.09, p 
0.05) and sepsis (OR 2.29, CI 1.01–5.22, p  0.05) with
the timing of diagnosis of maternal hypothyroidism,
with higher chance in those diagnosed prior to preg-
nancy. Premature birth is a known complication of
maternal hypothyroidism as reported in many studies
[18,48,49], however, there are studies which have also
shown no such association [45]. Differences in opinion
may be due to heterogenous population and differen-
ces in study design, most of the data being retrospect-
ively collected or retrieved from birth registries.
Similarly, neonatal sepsis has been well reported in
association with maternal hypothyroidism (a OR 1.42,
95% CI 1.16–1.74) [30]. When reviewing these studies
in detail, none have compared these outcomes with
respect to the timing of diagnosis of maternal
hypothyroidism.
In conclusion, our study described hyperbilirubinae-
mia as the most common neonatal outcome and car-
diovascular defects as the most common major
congenital anomaly. There is significant association of
congenital anomalies and low birth weight with the
timing of diagnosis of hypothyroidism in women.
Moreover, premature birth and neonatal sepsis is also
associated in this respect with marginal significance.
Our study also has a limitation with regards to selec-
tion bias. We observed higher congenital anomalies
and conditions in neonates born to women diagnosed
during pregnancy. As this is a single hospital study,
women with known hypothyroidism could have been
more likely referred into our hospital for the high-risk
obstetrical care with lessor congenital defects. Despite
of all the limitations associated with a retrospective
study design, this is the first study reporting neonatal
outcomes and congenital anomalies of hypothyroid
pregnancies from Pakistan. We propose to do multi-
centre prospective studies to determine the associ-
ation of congenital anomalies in neonates of uncon-
trolled hypothyroid mothers either diagnosed before
or during pregnancy with adequate levothyroxine
replacement. We also recommend to perform case–
control studies to determine the effects of hypothy-
roid pregnancies on the neonatal outcomes, whether
diagnosed before pregnancy or anytime dur-
ing gestation.
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